Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 8, 2012 - Issue 7: Special Focus: Transplantation: from tolerance to rejection
Submit an article Journal homepage
41
Views
6
CrossRef citations to date
0
Altmetric
Review

Hepatitis C virus recurrence and immunosuppression-free state after liver transplantation

Tommaso Maria Manzia UOC Trapianti d’Organo, Tor Vergata University, Rome, Italy; UOC Trapianti d’Organo, Tor Vergata University, Rome, Italy. [email protected]
,
Roberta Angelico UOC Trapianti d’Organo, Tor Vergata University, Rome, Italy; UOC Trapianti d’Organo, Tor Vergata University, Rome, Italy
,
Luca Toti UOC Trapianti d’Organo, Tor Vergata University, Rome, Italy; UOC Trapianti d’Organo, Tor Vergata University, Rome, Italy
,
Quirino Lai Cliniques Universitaires Saint Luc, Brussels, Belgium; Cliniques Universitaires Saint Luc, Brussels, Belgium
,
Paolo Ciano UOC Trapianti d’Organo, Tor Vergata University, Rome, Italy; UOC Trapianti d’Organo, Tor Vergata University, Rome, Italy
,
Mario Angelico Department of Internal Medicine, Hepatology Unit, Tor Vergata University, Rome, Italy; Department of Internal Medicine, Hepatology Unit, Tor Vergata University, Rome, Italy
&
Giuseppe Tisone UOC Trapianti d’Organo, Tor Vergata University, Rome, Italy; UOC Trapianti d’Organo, Tor Vergata University, Rome, Italy
 show all
Pages 635-644 | Published online: 10 Jan 2014

References

  • Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J. Hepatol. 35(5), 666–678 (2001).
  • Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am. J. Transplant. 9(8), 1707–1713 (2009).
  • Gonzalez SA. Management of recurrent hepatitis C following liver transplantation. Gastroenterol. Hepatol. (N. Y). 6(10), 637–645 (2010).
  • Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int. 32(Suppl. 1), 120–128 (2012).
  • Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J. Hepatol. 56(4), 973–983 (2012).
  • Trotter JF. Hot-topic debate on hepatitis C virus: the type of immunosuppression matters. Liver Transpl. 17(Suppl. 3), S20–S23 (2011).
  • Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl. 9(11), S63–S66 (2003).
  • Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J. Hepatol. 50(6), 1247–1257 (2009).
  • Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am. J. Transplant. 6(8), 1774–1780 (2006).
  • McCaughan GW, Shackel NA, Bertolino P, Bowen DG. Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes. Transplantation 87(8), 1105–1111 (2009).
  • Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J. Hepatol. 32(4), 673–684 (2000).
  • Rubín A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin. Res. Hepatol. Gastroenterol. 35(12), 805–812 (2011).
  • Graziadei IW, Zoller HM, Schloegl A et al. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl. 18(6), 671–679 (2012).
  • Belli LS, Burra P, Poli F et al. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 130(3), 695–702 (2006).
  • Charlton MR, Thompson A, Veldt BJ et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53(1), 317–324 (2011).
  • Fukuhara T, Taketomi A, Motomura T et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139(5), 1577–85, 1585.e1 (2010).
  • Ducoulombier D, Roque-Afonso AM, Di Liberto G et al. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 39(3), 817–825 (2004).
  • Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Invest. 119(7), 1745–1754 (2009).
  • Chinnadurai R, Velazquez V, Grakoui A. Hepatic transplant and HCV: a new playground for an old virus. Am. J. Transplant. 12(2), 298–305 (2012).
  • Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305(5685), 872–874 (2004).
  • Neumann UP, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J. Hepatol. 41(5), 830–836 (2004).
  • Ramírez S, Pérez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl. 14(Suppl. 2), S27–S35 (2008).
  • Rosen HR. Transplantation immunology: what the clinician needs to know for immunotherapy. Gastroenterology 134(6), 1789–1801 (2008).
  • Saito T, Gale M Jr. Regulation of innate immunity against hepatitis C virus infection. Hepatol. Res. 38(2), 115–122 (2008).
  • Rosen HR, Doherty DG, Madrigal-Estebas L, O’Farrelly C, Golden-Mason L. Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl. 14(1), 31–40 (2008).
  • Weston SJ, Leistikow RL, Reddy KR et al. Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation. Hepatology 41(1), 72–81 (2005).
  • Berenguer M, Aguilera V, Prieto M et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J. Hepatol. 44(4), 717–722 (2006).
  • Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 12(8), 1192–1204 (2006).
  • Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J. Hepatol. 49(2), 274–287 (2008).
  • Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am. J. Transplant. 6(7), 1586–1599 (2006).
  • Xirouchakis E, Triantos C, Manousou P et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J. Viral Hepat. 15(10), 699–709 (2008).
  • Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int. 31(Suppl. 1), 68–77 (2011).
  • Berenguer M. Hot topic in hepatitis C virus research: the type of immunosuppression does not matter. Liver Transpl. 17(Suppl. 3), S24–S28 (2011).
  • Nakagawa M, Sakamoto N, Tanabe Y et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 129(3), 1031–1041 (2005).
  • Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38(5), 1282–1288 (2003).
  • Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 13(1), 21–29 (2007).
  • Germani G, Pleguezuelo M, Villamil F et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am. J. Transplant. 9(8), 1725–1731 (2009).
  • Manzia TM, Angelico R, Toti L et al. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl. Int. 24(5), 461–468 (2011).
  • Bahra M, Neumann UI, Jacob D et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am. J. Transplant. 5(2), 406–411 (2005).
  • Veldt BJ, Poterucha JJ, Watt KD et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am. J. Transplant. 9(6), 1406–1413 (2009).
  • Foxton MR, Quaglia A, Muiesan P et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am. J. Transplant. 6(8), 1922–1929 (2006).
  • Orlando G, Hematti P, Stratta RJ et al. Clinical operational tolerance after renal transplantation: current status and future challenges. Ann. Surg. 252(6), 915–928 (2010).
  • Karam VH, Gasquet I, Delvart V et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 76(12), 1699–1704 (2003).
  • Josh L. Operational tolerance: past lessons and future prospects. Liver transpl. 17, 222–232 (2011).
  • Sánchez-Fueyo A. Identification of tolerant recipients following liver transplantation. Int. Immunopharmacol. 10(12), 1501–1504 (2010).
  • Sánchez-Fueyo A. Hot-topic debate on tolerance: immunosuppression withdrawal. Liver Transpl. 17(Suppl. 3), S69–S73 (2011).
  • Orlando G. Finding the right time for weaning off immunosuppression in solid organ transplant recipients. Expert Rev. Clin. Immunol. 6(6), 879–892 (2010).
  • Starzl TE, Demetris AJ, Trucco M et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 17(6), 1127–1152 (1993).
  • Reyes J, Zeevi A, Ramos H et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant. Proc. 25(6), 3315–3319 (1993).
  • Ramos HC, Reyes J, Abu-Elmagd K et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 59(2), 212–217 (1995).
  • Tzakis AG, Reyes J, Zeevi A et al. Early tolerance in pediatric liver allograft recipients. J. Pediatr. Surg. 29(6), 754–756 (1994).
  • Mazariegos GV, Reyes J, Marino IR et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 63(2), 243–249 (1997).
  • Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl. Immunol. 17(2), 114–119 (2007).
  • Devlin J, Doherty D, Thomson L et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 27(4), 926–933 (1998).
  • Girlanda R, Rela M, Williams R, O’Grady JG, Heaton ND. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant. Proc. 37(4), 1708–1709 (2005).
  • Andreoni KA, Lin JI, Groben PA. Liver transplantation 27 years after bone marrow transplantation from the same living donor. N. Engl. J. Med. 350(25), 2624–2625 (2004).
  • Eason JD, Cohen AJ, Nair S, Alcantera T, Loss GE. Tolerance: is it worth the risk? Transplantation 79(9), 1157–1159 (2005).
  • Tryphonopoulos P, Tzakis AG, Weppler D et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am. J. Transplant. 5(3), 608–613 (2005).
  • Tryphonopoulos P, Ruiz P, Weppler D et al. Long-term follow-up of 23 operational tolerant liver transplant recipients. Transplantation 90(12), 1556–1561 (2010).
  • Tisone G, Orlando G, Cardillo A et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J. Hepatol. 44(4), 702–709 (2006).
  • Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl. Immunol. 20(1–2), 43–47 (2008).
  • Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22(6), 696–699 (1995).
  • Manzia TM, Cillis A, Angelico R et al. Ten years of weaning-off immunosuppression in stable HCV liver transplant recipients. Presented at: American Transplant Congress. Philadelphia, PA, USA, 30 April–4 May 2011.
  • Martínez-Llordella M, Puig-Pey I, Orlando G et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am. J. Transplant. 7(2), 309–319 (2007).
  • Martínez-Llordella M, Lozano JJ, Puig-Pey I et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J. Clin. Invest. 118(8), 2845–2857 (2008).
  • Bohne F, Martínez-Llordella M, Lozano JJ et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J. Clin. Invest. 122(1), 368–382 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.